LAWRENCE, EVANS & CO., LLC

Investment Banking | Healthcare Finance | Consulting

Healthcare Weekly News and Deals –Sept 8th, 2026

1. **Oura Inc. has publicly filed its Form S-1 with the SEC for a Nasdaq listing under the ticker OURA, with existing investors reportedly seeking up to $3 billion at a valuation above $16 billion.**

   The public file on 3 September replaces a 21 May confidential submission and attaches audited figures. Revenue reached $1.21 billion for the nine months to 30 June 2026, up 74% from $697.6 million; fiscal 2025 revenue was $907.9 million, up 123%. Gross margin improved to 55% from 51%. The $924.3 million net loss attributable to common stockholders is a $985.0 million deemed dividend on redeemable convertible preferred — a pre-IPO capital-structure entry, not operating deterioration. Last private mark was about $11 billion in October 2025. Hardware is still roughly 80% of revenue. (Link)

2. **Yellow Wood Partners to Buy Nestlé's Mainstream Vitamins and Supplements Platform for $1 Billion**

   Nestlé is keeping the premium practitioner-channel brands — Solgar and Pure Encapsulations — and selling the mass-market Holistic Health VMS book. That is how large strategics are now splitting consumer health: retain clinician-recommended margin, exit volume. Yellow Wood has run this carve-out playbook before. GLP-1-driven changes in nutrition behavior are reshuffling category economics; add-on activity is expected. (Link)

3. **Medtronic plc has committed about $700 million to Cornerstone Robotics and taken distribution rights to Cornerstone's Sentire surgical system in selected markets outside the United States.**

   Sentire will sit beside Hugo (Medtronic's robotic-assisted surgery (RAS) system) rather than replace it. The system was built in-house, finished multi-specialty trials and received CE Mark in May 2026 for general, gynecologic, thoracic and urologic minimally invasive surgery, on top of China and Singapore approvals. Cornerstone runs three global R&D hubs, six business centers and a 30,000-square-meter plant in China; the console is dual-capable. Hugo is already in more than 35 countries, with procedures expected to exceed 50,000 this fiscal year. Rights apply only where Sentire is already market-approved. (Link)

4. **American Healthcare REIT Spends $696 Million on Eight Class A Senior Housing Communities, Launching a New LCB Operating Relationship**

   The eight communities total 867 units across Massachusetts, Connecticut, New Jersey, Pennsylvania, Delaware and Georgia. They were carved from a ten-community sale; AHR walked the other two to a second buyer at its allocated basis — a structure owners should note when a single buyer will not take the whole book. The same week AHR closed six Kensington Senior Living communities for about $572 million, part of an eight-community, 745-unit portfolio priced near $873 million and described as well below replacement cost. Year-to-date investments now exceed $2 billion. (Link)

5. LTC Properties Pays $200 Million for Four Minnesota SHOP Communities at a 7% Year-One Cap Rate

   The four assets are 453 independent living, assisted living and memory-care units with an average age of nine years. Unlevered IRR is guided to the low- to mid-teens. About $167 million of the check came from selling 13 Texas skilled-nursing centers — a rotation out of triple-net SNF into operator-aligned seniors housing, now 38% of annualized NOI. Operator is Lifespark. Published cap-rate and IRR targets are uncommon and give private owners a reference bid. (Link)

6. Medtronic plc (NYSE: MDT) has agreed to invest up to $80 million in Israel's Pi-Cardia Ltd., securing global distribution rights to the ShortCut device and an option to acquire the company for up to $210 million plus earn-outs.

   The check is staged into Rehovot; exclusive ShortCut distribution starts in 2027; the option is milestone-based. ShortCut is the first FDA-cleared leaflet-modification tool for valve-in-valve TAVR patients at risk of coronary obstruction, with successful leaflet splitting in every pivotal-trial patient. Structural Heart GM Jorie Soskin framed it as preparing for complex-anatomy TAVR demand rather than buying the company today. (Link)

7. Cresco Labs Inc. (CSE: CL; OTCQX: CRLBF) has closed the purchase of PharmaCann Penn, LLC for $50 million in cash and a seller note, adding nine operating medical-marijuana dispensaries in Pennsylvania

   The deal is cash-free and debt-free against a normalized working-capital target and is described as immediately accretive to revenue, margin and cash flow. Pennsylvania is the second-largest U.S. medical cannabis market, with more than $1.1 billion of sales last year. The stores deepen an existing Mid-Atlantic retail bench rather than opening a new state. No earn-out was disclosed. (Link)

8. Fortrea Holdings Inc. (NASD: FTRE) will buy Worldwide Clinical Trials' Early Phase Services unit for about $45 million in cash.

   The package is a 200-bed GCP clinical pharmacology unit in San Antonio, a 60,000-square-foot GLP bioanalytical lab in Austin and a biospecimen store in Pflugerville. Fortrea picks up captive large- and small-molecule bioanalysis and more first-in-human beds. Worldwide keeps late-stage oncology, neuroscience, internal medicine and rare disease and will still place Phase I work through a services alliance. Close is subject to licenses and those agreements. Barclays and Mintz advised Fortrea; BroadOak and Greenberg Traurig advised Worldwide. (Link)

9. Discovery's Vitality Acquires Icario in a Reported R958 Million Deal, Building a Payer Platform Covering 30% of U.S. Health Plans

   The combined stack reaches 19 million members, including eight of the ten largest U.S. plans. The parties themselves did not disclose value; the R958 million figure is from South African press. Member engagement is now a Stars-and-risk-adjustment revenue lever rather than a wellness line item. The buyer is a non-U.S. strategic writing a check for scaled U.S. payer distribution — a class domestic sellers should not overlook. (Link)

10. HCA Healthcare, Inc. (NYSE: HCA) has sold Dominion Hospital in Falls Church, Virginia to New York-based senior care operator Hill Valley Healthcare for $25 million.

    The buyer, founded in 2018, runs more than 40 facilities across six states. This is its first behavioural-health asset and part of a push into Virginia. Dominion treats children, adolescents and adults, including eating-disorder and trauma programmes. HCA keeps 430 inpatient behavioural beds and 19 outpatient programmes in the state. (Link)

11. PACS Group, Inc. (NYSE: PACS) has signed definitive agreements to acquire the operations of 32 Florida skilled nursing facilities leased from Omega Healthcare Investors, Inc. (NYSE: OHI).

    Florida is the company's 21st state. The package adds 4,049 licensed beds concentrated in the Tampa, St. Petersburg and Orlando corridor, with close expected in the fourth quarter. Chairman and CEO Jason Murray framed the state as demographically driven growth; shares rose 3.3% premarket. (Link)

12. H.I.G. Capital has completed the acquisition of Outcomes One, the Orlando-based clinical network services and pharmacy technology provider led by Chief Executive Jude Dieterman.

    The Miami firm, with $75 billion under management, bought through an affiliate; terms were undisclosed. The asset pairs network reach with recurring software: a clinical network touching roughly 85% of U.S. pharmacies, more than 10 million interventions in 2025 across 130 million covered lives, and platforms including Rx30, Computer-Rx and Outcomes Premium. Managing Director Arjun Mohan framed the thesis as elevating the pharmacy's role in care delivery. Customers span national chains, health systems, specialty and long-term care, and independents. (Link)

13. CVC, through its Strategic Opportunities III platform, has agreed to invest in Unitex Textile Services LLC alongside the Potack family, taking the first outside equity in the healthcare linen group's 100-year history.

    Founded in 1922 and based in Elmsford, New York, Unitex is the leading outsourced healthcare textile manager in the Northeast, serving more than 5,000 hospitals, outpatient sites and nursing homes through an automated processing network. Chairman Michael, CEO Robert and President David Potack keep a significant stake and continue to run the company. Proceeds fund operations, commercial work, digital capability, greenfield sites and bolt-ons. The underwriting is scale, route density and long-tenured accounts. (Link)

14. Labcorp (NYSE: LH) has acquired MLM Medical Labs, expanding its central-laboratory and biomarker network across the United States, Germany and South Africa.

    Labcorp says that makes it the only independent central lab with a wholly owned network on four continents. MLM operates Africa's first fully CAP-accredited central laboratory and adds biomarker and specialty testing for multinational trials. Labcorp employs about 71,000 people, supported more than 85% of FDA new-drug approvals in 2025 and ran more than 750 million tests. No price was disclosed. (Link)

15. Bain Capital-backed LeanTaaS has acquired Aidin, the care transition platform founded and led by Russell Graney, to extend iQueue for Inpatient Flow through discharge and placement.

LeanTaaS is already in about 200 health systems and more than 1,200 facilities. Aidin serves 200-plus hospitals across roughly 20 systems and coordinates more than two million referrals a year through 21,000-plus post-acute providers. Published results: 0.86 days off average length of stay, placement time halved, and about $1.7 million of annual savings per hospital. Bain partner Paul Moskowitz framed the return as capturing both the avoided day and the freed bed. Terms undisclosed. (Link)

16. Stryker (NYSE: SYK) has signed a definitive agreement to acquire privately held ZuriMED, developer of the commercialized FiberLocker System for rotator-cuff augmentation.

ZuriMED is a Zurich company out of ETH Zurich, the University of Zurich and Balgrist. FiberLocker is an FDA-cleared (510(k), late 2024) single-use system: a non-degradable polyester SpeedPatch PET felt plus a dedicated instrument that mechanically felts the patch into repaired cuff tissue. Published retear rates after cuff repair run from 24% to 94%; the device is indicated to reinforce suture or anchor repair where the soft tissue is weak. The parties will operate separately until close. (Link)

17. Quva has acquired Central Admixture Pharmacy Services' 503B product portfolio after CAPS, a B. Braun unit, exited 503B sterile compounding.

Named SKUs include cardioplegia, total parenteral nutrition and heparin. Quva runs more than 200,000 square feet of FDA-registered 503B plants in New Jersey and Texas and 100,000 square feet of forward distribution in Texas and Arizona, and already serves more than 3,500 U.S. hospitals. Selected products start later in 2026, with the rest over the following six months. Local CAPS 503B staff are being offered roles. (Link)

18. VION Biosciences, based in Shaker Heights, Ohio, has closed its acquisition of Prolytix.

The add-on brings regulated large-molecule bioanalytical and CMC work — PK, ADA and immunogenicity, biomarkers, method validation, release and stability — plus research reagents, plasma and coagulation proteins, IVD inputs and custom collection devices. Those lines sit next to CTL immune monitoring and Ansh Labs on a Brooke PE / LongWater / Twin Bridge platform. CEO Mark Thornton framed the gap as documentation-heavy services and workflow-critical reagents. (Link)

19. Serent Capital-backed Aria Care Partners has acquired Precision Mobile Care, the Utah mobile dental provider led by Principal John Flanders.

The Overland Park platform already delivers dental, vision, audiology and podiatry plus insurance into skilled nursing facilities and has converted a ten-year insurance relationship into ownership. Precision serves thousands of residents in more than half of Utah's SNFs with on-site preventive and restorative dental care. This is Aria's third acquisition of 2026, after the February Sanford dental and vision platform in Georgia and Alabama. Aria partners with more than 3,500 facilities nationally; client-facing teams and schedules stay. (Link)

20. Incline Equity Partners-backed West Physics Consulting, LLC has acquired Radiographic Testing Services, Inc., the Albany, New York medical physics provider.
    West Physics, Atlanta-based and sponsor-backed since June, is on its ninth disclosed add-on. RTS, founded in 2011, covers nuclear medicine, diagnostic radiology, radiation oncology and Certified Radiation Equipment Safety Officer work across central New York. An Albany field office lets the platform meet New York requirements centrally and reach Boston and Philadelphia. CEO Dr. Geoffrey West cited local relationships and state regulatory familiarity. (Link)

Venture Deals and Other

1. Noteus Partners has led a $90 million equity round in Scan.com with participation from Aviva (LSE: AV.), Concord Health Partners, YZR Capital and Oxford Capital, alongside $130 million of debt facilities from VerisFi Capital and Atempo Growth.
   Combined capital is $220 million after revenue doubled to a $165 million annualised run-rate. The debt is earmarked for M&A and working capital in a U.S. imaging market where 85% of scans are still booked by fax or phone. Noteus GP Nathalie Bruls cited patient experience, provider connectivity and proprietary data; Concord's James Olsen tied it to access and cost. More than 900,000 patients have used the network globally. (Link)

2. Morgan Health has led a Series E of more than $125 million in Thyme Care at a valuation above $2 billion, joined by Humana Inc. (NYSE: HUM), CVS Health Ventures — the corporate arm of CVS Health Corporation (NYSE: CVS) — AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health.
   The syndicate pairs two national payers with community-oncology, health-system and employer-benefit capital. Reach is 10.5 million people across all 50 states and more than $7 billion of oncology spend, with validated 5–10% reductions in total cost of care. The company reports profitability and positive free cash flow. Proceeds also capitalise Thyme Companies, a new parent building independent oncology businesses aimed at biosimilar adoption and trial accrual. Morgan Health CEO Dan Mendelson cited continued conviction in payer-side value delivery. (Link)

3. Ultrahuman has raised $70 million — $65 million of equity and $5 million of debt — at a reported $365 million valuation, with Qualcomm Ventures, Labcorp, Alpha Wave, Blume Ventures, Nexus Venture Partners and Alteria Capital.
   The Bengaluru company says it has sold about 800,000 rings and is running at a $140 million revenue run-rate, targeting $200 million by January 2027. It currently uses Nordic Semiconductor silicon and is adding Qualcomm chips so more algorithms run on the ring rather than the phone or cloud. Part of the money funds a deeper link between ring physiology and Labcorp blood-testing data, plus expansion in India and the UAE. (Link)

4. **BVF Partners, L.P. has led an oversubscribed $60 million Series B in Superluminal Medicines with new investors Deep Track Capital and Perceptive Advisors joining existing backers RA Capital Management, Insight Partners, NVIDIA Corporation (NASD: NVDA), Catalio Capital Management, Eli Lilly and Company (NYSE: LLY), Cooley and Gaingels.**

   The round funds the move from discovery platform to clinic. NVIDIA is the compute check; Lilly is both investor and GPCR collaboration partner. Proceeds take a selective, biased MC4R agonist into Phase 1 by year-end 2026 for rare genetic and hypothalamic obesity. BVF's Harsha Paladugu cited differentiated small molecules against historically intractable GPCRs; RA Capital's Nandita Shangari pointed to syndicate calibre as validation of platform translation. (Link)

5. **Elucid has closed an oversubscribed $55 million Series D with a new unnamed publicly traded medtech strategic investor joining IAG Capital Partners and Elevage Medical Technologies, the platform created by Patient Square Capital.**

   The company raised after FDA clearance and reimbursement, not before. Total capital is about $185 million since 2009; valuation undisclosed. The new backer is Elucid's fourth publicly traded strategic — an unusual concentration for software-only cardiovascular diagnostics. Plaque-IQ was cleared in October 2024 and has been reimbursable under CPT 75577 at a national average of about $1,012 per scan since January 2026. BioIntegrated FFR-CT remains in 510(k). Proceeds fund commercial expansion and clinical studies. (Link)

6. **Hi Rasmus has taken a $50 million minority growth-equity investment from Updata Partners.**

   The Nashville ABA software company was founder-controlled and previously bootstrapped. It now serves about 1,000 organizations and 19.6 million client session hours a year and ranked No. 7 on the 2026 Inc. Regionals Southeast list on 1,069% two-year growth. Braden Snyder of Updata joins the board. No change of control; management says it does not plan another raise. (Link)

7. **EIT Pharma has closed an oversubscribed $35 million Series A led by Propel Bio Partners. Kirkland, Wash.–based EIT is taking lonafarnib, an investigational first-in-class oral therapy for chronic hepatitis D in patients already infected with hepatitis B, through FDA review.**

   The company says it is the only oral candidate in late-stage CHD development and that the NDA has been accepted. Lonafarnib is designed for oral dosing and room-temperature storage. Good Ventures and Arrowtown joined. Proceeds fund continued FDA review, manufacturing and commercial readiness if approved, plus the rest of the infectious-disease pipeline. Safety and efficacy are not established. (Link)

8. **Labcorp Venture Fund, the strategic arm of Labcorp Holdings Inc. (NYSE: LH), has led a $32 million Series B in N-Power Medicine with continued participation from the Merck Global Health Innovation Fund of Merck & Co., Inc. (NYSE: MRK), Innovatus Capital Partners and a leading US biotech investor.**

   The Labcorp check is the second industry-leader investment in the Redwood City company after Merck GHI. The product is ProECA, which builds prospective, trial-grade external control arms from routine community cancer care and is meant to cut randomisation, sample size and timelines. The initial NSCLC programme runs across more than 40 community oncology sites and is already used by sponsors for early-phase and Phase 4 work. Colorectal and prostate platforms follow later this year. Proceeds scale the network and pharma partnerships. (Link)

9. **Chicago-based PatientIQ has closed a $30 million Series C led by Hughes & Company, with Health Enterprise Partners and August Capital.**

   The outcomes platform now covers 870-plus healthcare organizations, 17 million patients and more than 70 million collected outcomes across 20-plus specialties and 50-plus EHR integrations, including Epic, Oracle Cerner and Athenahealth. It powers registries for AAOS, AANS and STS. Proceeds fund deeper specialty and health-system penetration, real-world evidence for device and life-science customers, and a direct-to-patient marketplace. Travis Hughes joins the board. (Link)

10. **Madrona and General Catalyst have led the close of NewDays' seed round at $16 million, as the Seattle AI dementia care company launches in Nevada.**

    The same pair co-led the original $7 million seed; this take-up brings the seed to $16 million total. The pitch is a staffing bottleneck: cognitive therapies work but depend on a small bench of trained clinicians. NewDays pairs monthly or twice-monthly telehealth visits with unlimited sessions with an AI companion, Sunny. Research presented at the Alzheimer's Association International Conference in July showed patients outperforming historical decline curves by about 18 months of preserved function — on 24 patients. Nevada is the sixth state. (Link)